Detalhe da pesquisa
1.
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Clin Gastroenterol Hepatol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447814
2.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet
; 379(9835): 2429-2438, 2012 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22748590
3.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet
; 379(9835): 2439-2448, 2012 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22748591
4.
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
HIV Clin Trials
; 14(5): 216-23, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24144898
5.
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
JHEP Rep
; 5(1): 100563, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36644237
6.
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
; 8(12): 1080-1093, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802088
7.
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Nat Med
; 27(7): 1262-1271, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239138
8.
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Clin Pharmacokinet
; 45(11): 1115-24, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17048975
9.
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Pharmacotherapy
; 24(8): 970-7, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15338845
10.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
J Acquir Immune Defic Syndr
; 63(4): 449-55, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23807155
11.
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
AIDS
; 25(6): F7-12, 2011 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21412057
12.
The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers.
Antivir Ther
; 15(2): 227-33, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20386078
13.
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Pediatrics
; 118(3): e711-8, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16923923
14.
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Pediatrics
; 116(6): e846-54, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16291735
15.
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.
Antimicrob Agents Chemother
; 48(1): 124-9, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14693529